Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.
KAUST's Laboratory of Stem Cells and Diseases, led by Assistant Professor Antonio Adamo, uses induced pluripotent stem cells (iPSCs) to model diseases like diabetes. The lab employs a reprogramming technique to revert patient fibroblasts into iPSCs, enabling the study of disease progression in vitro. Adamo's research focuses on enzymes and disregulated transcriptional/epigenetic mechanisms to understand disease onset. Why it matters: This research contributes to regenerative medicine and offers insights into metabolic diseases relevant to the GCC region.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.
MBZUAI researchers are working on digital twin technology that can replicate human beings in detail, with real-time data flow between the physical and virtual. This project aims to extend digital twins from objects to organic entities like humans, plants and animals. The technology mines data from cameras, sensors, wearables, and other sources to predict health issues before they arise. Why it matters: This research has the potential to transform healthcare by enabling the prediction and prevention of health issues.
Khaled Alsayegh at the King Abdullah International Medical Research Center is creating a Saudi Stem Cell Donor Registry, with 80,000 potential donors identified. The aim is to identify universal donors, reprogram their cells into induced pluripotent stem (iPS) cells, and create a gene bank for matched tissue transplants. Alsayegh is collaborating with Jesper Tegnér at KAUST to create pacemaker cells using single-cell RNA sequencing. Why it matters: This initiative could revolutionize precision medicine in KSA by providing readily available, matched cells for transplants, reducing the need for patient-specific reprogramming and improving treatment outcomes.
A KAUST team led by Hossein Fariborzi won second place in the MEMS Design Contest for their "MEMS Resonator for Oscillator, Tunable Filter and Re-Programmable Logic Applications." The device is runtime-reprogrammable, allowing the function of each device in the circuit to be changed during operation. The KAUST team demonstrated that two MEMS resonators could replace over 20 transistors in applications like digital adders, reducing digital circuit complexity. Why it matters: This innovation could significantly reduce power consumption, chip area, and manufacturing costs in microprocessors, advancing the development of energy-efficient microcomputers in the region.
MBZUAI is developing AI algorithms to intelligently process data from wearables and home sensors for remote patient monitoring. The algorithms aim to analyze multiple strands of health data to provide a more comprehensive view of a patient's health, distinguishing between genuine emergencies and benign situations. MBZUAI's provost, Professor Fakhri Karray, believes this approach could handle 20-25% of diagnoses virtually, reducing the burden on healthcare systems. Why it matters: This research could significantly improve healthcare efficiency and accessibility in the UAE and beyond by enabling more effective remote patient monitoring and reducing unnecessary hospital visits.
Researchers at KAUST and Peking University Third Hospital have created a novel blastoid model for studying early human development using extended pluripotent stem cells (EPSCs). The blastoid is a 3D cell model mimicking the blastocyst phase, avoiding ethical concerns associated with using human embryos. The team showed that blastoids can be cultured to mimic post-implantation development, offering insights into early cell lineages. Why it matters: This innovation provides a way to study human embryogenesis without the ethical constraints of using actual embryos, potentially advancing our understanding of miscarriage and birth defects.